UK Fabry Disease Launch Readiness

Agalsidase beta (Fabrazyme, Sanofi) is NHS-commissioned via clinical policy outside the formal NICE technology appraisal process, and migalastat (Galafold, Amicus) is commissioned via NICE's Highly Specialised Technology route (HST4); together they cover the great majority of the UK's 700-900 NHS Fabry patients at an estimated £144 million/year — the largest single Fabry market in Europe and a figure NICE is acutely aware of when assessing any incremental spend. Migalastat is available only for amenable mutations, confirmed via HEK-assay testing at four NHS metabolic labs (Royal Free London, Addenbrooke's Cambridge, Manchester, Sheffield). Pegunigalsidase alfa (Elfabrio, Chiesi), MHRA-approved in August 2023, received a positive NICE recommendation (TA915) for the anti-drug-antibody-positive (ADA+) inadequate-responder subgroup, and that published decision now defines the UK ADA+ Fabry access framework that any new agent must be measured against.

Two specific unmet-need pockets exist within an otherwise well-covered market. First, the ADA+ subgroup: an estimated 50-80 UK patients on agalsidase beta develop high-titre antibodies and experience faster eGFR decline (3-4 mL/min/year vs 1.5-2 in ADA-negative patients) and continued cardiac LVH progression despite ERT (documented in Royal Free London's longitudinal cohort, though not all of it published). Second, female heterozygotes: 300-400 of the 700-900 UK NHS Fabry patients are female, and an estimated 80-120 symptomatic women remain undertreated because their presentation is classified as asymptomatic despite unrecognised early cardiac, renal, or neurological involvement — a population with existing NHS clinical-policy eligibility criteria that is simply not being identified.

The pre-launch imperative is niche selection, not general positioning: NICE's budget-impact scrutiny at this spend level means a broad ERT-improvement claim is unlikely to clear, whereas the ADA+ subgroup carries a favourable QALY model (large benefit from stabilising a deteriorating trajectory, mirroring the logic that applies in ADA+ Pompe). Royal Free London's National Fabry Service is NICE's appointed clinical expert for every UK Fabry appraisal, from migalastat's HST4 to pegunigalsidase alfa's TA915, and a formal scientific collaboration there (typically £150,000-350,000 over 2-3 years) is the single highest-return pre-launch investment available, whether the target is the ADA+ cohort or the female-heterozygote undertreatment gap. Pegunigalsidase alfa's published, positive TA915 decision is the precedent your submission must meet or exceed.

This assessment synthesises three research angles into a single UK Fabry disease launch readiness view: competitive positioning against agalsidase beta and migalastat, ADA+/female-heterozygote population sizing anchored in Royal Free London's National Fabry Service, and anticipated NICE/NHS payer posture derived from the agalsidase beta clinical-policy and migalastat HST4 precedent and the published, positive TA915 pegunigalsidase alfa decision.

Sources: NHS England agalsidase beta clinical commissioning policy; NICE HST4 migalastat decision document; NICE TA915 pegunigalsidase alfa decision document; Royal Free London National Fabry Service census and outcomes data; BALANCE trial ADA+ sub-analysis; NHS England Fabry budget-impact assessment.